Design It In: Why Your R&D Phase Is the Best Time to Choose VHP Sterilization

Most medical device development teams treat sterilization as a late-stage procurement decision. Design the device. Freeze the materials. Select the packaging. Then — somewhere between design verification and design transfer — figure out how the product will be sterilized and which contract sterilizer will run it.

This sequence is deeply embedded in how the industry operates, and it is one of the most expensive mistakes a small or mid-size manufacturer can make. The sterilization method is not a downstream logistics question. It is a design parameter — one that constrains material selection, packaging design, regulatory submission strategy, and supply chain architecture from the moment it is chosen. The manufacturers who recognize this early design it in. Those who do not discover it late, after design freeze, when every change has a cost.

The Cost of Choosing Late

The practical consequences of deferring sterilization method selection are well understood by anyone who has navigated a late-stage material incompatibility or a regulatory supplement triggered by a sterilization change.

Here is what the late-selection sequence looks like in practice: a device is designed, materials are specified, packaging is selected, and a contract EtO sterilizer is identified. Validation begins. Material compatibility testing reveals that a critical adhesive or polymer component absorbs ethylene oxide residue in ways that cannot be cleared to ISO 10993-7 limits within an acceptable aeration window. The choices at that point are expensive: re-engineer the component, reselect the material, change the packaging configuration, or change the sterilization method. Any of these triggers a partial or complete design change — which under FDA QMSR (effective February 2, 2026) and ISO 13485:2016 Clause 7.3 requires a formal design change review, impact assessment, and potentially revalidation of downstream processes. For a small manufacturer with limited engineering bandwidth, this is not a minor setback. It is a program-level event.

The same logic applies to irradiation. A drug-coated combination device that encounters gamma irradiation late in development — after the coating formulation is finalized — may find that the radiation dose required for SAL 10⁻⁶ degrades the drug constituent in ways that shift elution kinetics or reduce delivered dose. The FDA's own guidance on combination product development identifies terminal sterilization as a process that can alter drug or biologic constituent quality attributes. Discovering this after design freeze means either reformulating the coating (a substantial development task) or changing the sterilization method (a substantial regulatory task).

Choosing sterilization method during R&D — not after — eliminates these scenarios by making material compatibility a design requirement from the beginning rather than a validation surprise at the end.

The FDA Is Now Explicit About This

The FDA's May 2024 Medical Device Sterilization Town Hall on sterilization method selection for new and existing devices was the seventh in an ongoing series focused on moving the industry toward deliberate, early sterilization method decisions rather than default late-stage choices. The message from CDRH has been consistent: sterilization is a critical process parameter that must be evaluated during design and development, not assigned after design freeze.

Under QMSR (21 CFR Part 820, effective February 2026), which incorporates ISO 13485:2016 by reference, risk management is required throughout product realization — not as a standalone activity at design transfer, but as an integrated element of design and development (ISO 13485 Clause 7.1). Sterilization method selection is a risk-based design decision: the wrong method for the device's materials, geometry, or intended use creates a measurable risk that must be identified, evaluated, and controlled. The new Compliance Program 7382.850 — the framework FDA investigators now follow for device manufacturer inspections — emphasizes lifecycle accountability and risk integration across all production and service provision activities. Sterilization process controls are explicitly within scope.

This is not theoretical regulatory pressure. It is the inspection framework in effect now. Device manufacturers whose design history files do not document sterilization method selection as a deliberate, risk-evaluated decision are exposed at their next FDA inspection in a way they were not under the prior QSR framework.

What VHP's Profile Means for Device Design

Vaporized hydrogen peroxide sterilization operates at temperatures between 25°C and 50°C with no ionizing radiation, no toxic gas residue, and no post-sterilization aeration requirement. Hydrogen peroxide vapor decomposes completely to water and oxygen. These characteristics are not incidental — they define a material compatibility envelope that aligns precisely with the product categories small and mid-size manufacturers are currently developing.

For the device categories that dominate current development pipelines, the material compatibility question often resolves itself in favor of VHP early in the analysis:

**Combination products with drug coatings** cannot tolerate sterilization methods that degrade the drug constituent. EtO's humidity and temperature conditions interact with drug-polymer matrices in ways that can shift elution profiles. Gamma irradiation denatures certain biologic constituents and causes chain scission in polymer drug carriers. VHP operates at low temperature without ionizing radiation — the drug coating encounters neither the thermal-humidity stress of EtO nor the free-radical attack of irradiation. The FDA's guidance on combination products makes the evaluation mandatory; for most drug-device combinations, VHP is the answer the evaluation produces.

**Bioabsorbable implants** made from polylactic acid, polyglycolic acid, and PLGA co-polymers are designed to degrade in the body over a defined timeline. Gamma and electron beam irradiation induce polymer chain scission that alters degradation kinetics — shifting the timeline the device was designed and validated around. EtO leaves residues that persist in materials designed to be absorbed by living tissue. VHP sterilization at low temperature, with no ionizing radiation and no residue, leaves the polymer chemistry unmodified. A 2026 study in Pharmaceutical Research confirmed VHP preservation of molecular weight and chemical integrity in PLGA, PLC, and TPU scaffolds — the baseline requirement for bioabsorbable device sterilization.

**3D-printed porous implants** present a specific EtO residue clearance challenge: the internal surface area created by porosity absorbs ethylene oxide and requires extended aeration. Published data on sterilization of 3D-printed medical devices consistently identifies VHP as the preferred method for preserving dimensional accuracy and material properties across the polymers used in additive manufacturing. For personalized and patient-matched devices — a growing category for small manufacturers — VHP's residue-free profile simplifies both validation and regulatory documentation.

Electronics-integrated devices — cardiac rhythm management devices, implantable sensors, wearable therapeutics — often contain components with moisture and temperature sensitivity that disqualifies steam sterilization and creates validation complexity for EtO humidity conditions. VHP's programmable humidity control allows cycles to be developed within the moisture tolerance window of sensitive electronics.

Temperature-sensitive and refrigerated products — a category addressed in depth in the companion piece in this series on in-house sterilization economics — cannot tolerate the cold chain break that irradiation requires. Shipping frozen or refrigerated product to a gamma irradiator on dry ice and re-establishing temperature control upon return is not merely inconvenient. It is a validated cold chain event with regulatory documentation requirements, a potential excursion event that threatens batch integrity, and an operational cost that compounds over every production run. In-house VHP at 25–50°C eliminates this entirely.

The Regulatory Pathway Advantage of Choosing VHP in R&D

In January 2024, the FDA formally reclassified VHP to Established Category A — placing it alongside steam, dry heat, EtO, and radiation as a recognized sterilization method with an established body of scientific evidence. ISO 22441:2022, recognized by FDA as a consensus standard, provides the complete validation framework: process development, performance qualification, and routine control.

For a device manufacturer filing a 510(k) or PMA, Category A recognition means the sterility section of the submission does not require extraordinary justification of the sterilization method itself. The evidentiary standard is: "we used an established method and here is our process validation." That is identical to the standard for steam, EtO, and radiation — the methods the FDA has accepted for decades.

A manufacturer who chooses VHP during R&D and designs the device's materials, packaging, and geometry around VHP compatibility arrives at their 510(k) submission with a sterility narrative that reads: "Terminal sterilization was performed using vaporized hydrogen peroxide sterilization, an Established Category A method per FDA's January 2024 guidance, validated per ISO 22441:2022." The validation documentation package — IQ/OQ/PQ, biological indicator data, residue testing, material compatibility — supports the submission directly.

A manufacturer who chose EtO or irradiation during R&D and discovers a problem during validation, then transitions to VHP, arrives at that same submission with a different narrative: "We changed our sterilization method during development, here is the rationale, here is the evidence that the change did not affect device performance, here is the revalidation." That is a longer, more complex sterility section — and it carries the implicit question of why the original method was chosen if it was not the right one.

The regulatory submission advantage of choosing correctly early is not that VHP is easier to justify than other established methods. It is that designing the device to be compatible with VHP from the beginning means there is no incompatibility story to explain.

Programmable Parametric Control: The Multi-SKU Advantage

Small and mid-size manufacturers rarely develop a single device in isolation. R&D pipelines typically include multiple products at different stages — a lead device approaching design freeze, an adjacent product in early development, a line extension in concept phase. Each has different materials, geometries, and packaging configurations.

The sterilization infrastructure choice made for the lead device becomes the infrastructure the entire pipeline inherits. A contract sterilization relationship with an EtO or irradiation provider that works for the lead device may be entirely wrong for the next product — creating a second contract relationship, a second validation effort, and a second supply chain dependency.

PuroGen's SteriFlex platform addresses this directly through programmable parametric control: independent control of VHP concentration, temperature, humidity, exposure time, and aeration profile. Each product in the manufacturer's portfolio can be validated against its own parameter set on the same system, with its own documentation trail. A bioabsorbable scaffold and a combination product and an electronics-integrated implant can each run their own validated cycle through a single SteriFlex system — not because the cycles are the same, but because the system is programmable enough to accommodate each one on its own terms.

For a small manufacturer building out a pipeline, this is not a feature. It is the architecture that makes a single sterilization investment scale across multiple products without multiple infrastructure decisions.

What "Designing It In" Actually Requires

Incorporating sterilization method selection into R&D does not require a dedicated sterilization engineer on staff. It requires asking three questions during design input definition — before material selection is finalized and before packaging is specified:

First: what are the material sensitivities of this device? Identify polymers, coatings, adhesives, and biologics that are sensitive to heat, ionizing radiation, humidity, or chemical residue. This analysis belongs in the design input documentation alongside mechanical, biocompatibility, and dimensional requirements.

Second: what are the sterilization method options given those sensitivities, and what is the regulatory pathway for each? For most novel device categories, this analysis will converge on a short list — and for the product categories described above, VHP will typically appear as the method with the fewest material compatibility constraints and the clearest regulatory pathway.

Third: what are the supply chain and custody implications of each method? If the device will be manufactured at low volume in a controlled environment, what does it mean to ship batches to a contract sterilizer's schedule? If the product is temperature-sensitive, what does the cold chain break look like operationally and what is the excursion risk per batch?

These questions, asked during design inputs, cost almost nothing to answer. Asked after design freeze, their answers can cost months and material program investment.

Frequently Asked Questions

**When in the development process should sterilization method selection happen?**

Sterilization method selection should occur during design input definition — before material selection is finalized and before packaging design begins. Under QMSR (21 CFR Part 820) and ISO 13485:2016, risk management is required throughout product realization beginning at design planning. Sterilization method selection is a risk-based design decision that affects material compatibility, packaging design, regulatory pathway, and supply chain architecture. Deferring it until after design freeze means making a consequential design decision without the information it generates.

**Does choosing VHP require building sterilization infrastructure during R&D?**

No. The sterilization method selection during R&D is a design decision, not a capital procurement decision. Selecting VHP during design inputs means designing materials, packaging, and geometry for VHP compatibility — which costs nothing and eliminates future incompatibility risk. The capital decision — whether to deploy an in-house VHP system or to use a VHP-capable contract sterilizer for early development — is a separate question that can be made when production volumes and timelines are better defined. PuroGen supports both pathways.

**What materials are incompatible with VHP sterilization?**

VHP has excellent material compatibility with the broad majority of polymers, metals, and composites used in medical device manufacturing. Known compatibility considerations include: certain cellulose-based packaging materials (which absorb VHP and can be addressed with non-cellulosic gas-permeable packaging such as Tyvek); some pressure-sensitive adhesives that degrade under VHP exposure; and select optical coatings that are sensitive to oxidative conditions. Material compatibility assessment is a standard component of the process development phase under ISO 22441:2022 and is conducted before cycle development begins. For most novel device categories — combination products, bioabsorbables, 3D-printed implants, electronics-integrated devices — VHP's material compatibility profile is more favorable than the alternatives.

**How does VHP sterilization fit into a 510(k) submission?**

VHP sterilization is an Established Category A method per FDA's January 2024 guidance. In a 510(k) submission, the sterility section must demonstrate that a validated sterilization process achieves SAL 10⁻⁶ using an established method or provide extended justification for a non-established method. VHP's Category A status means no extended justification is required — the submission documents the validated process per ISO 22441:2022, and FDA review proceeds on the same evidentiary basis as for steam, EtO, or radiation.

**What is the difference between choosing VHP for R&D prototypes versus production?**

Prototype sterilization during early R&D is typically not subject to the same validation requirements as production sterilization — devices used in bench testing and early feasibility work are not labeled as sterile and do not carry the same regulatory burden. The sterilization method selection decision that matters for submission purposes is the production sterilization process, which must be validated per ISO 22441:2022 before the device is labeled sterile. Selecting VHP early means the prototype and production processes are aligned — reducing the risk that compatibility issues discovered during production validation require design changes that affect prototype work already completed.